Your session is about to expire
← Back to Search
[68Ga]P15-041 for Prostate Cancer
Phase < 1
Waitlist Available
Research Sponsored by Five Eleven Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
histologically confirmed prostate cancer. known or suspected bone metastases referred for a clinical [99mTc]MDP scan
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 minutes post injection
Awards & highlights
Study Summary
This trial will test if a new imaging agent can help doctors better visualize and target prostate cancer that has spread to the bone.
Eligible Conditions
- Prostate Cancer
- Bone Metastases
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 minutes post injection
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 minutes post injection
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time course of uptake of [68Ga]P15-041 in bone metastases
Time course of whole body distribution of [68Ga]P15-041
Trial Design
2Treatment groups
Experimental Treatment
Group I: Whole body dosimetry groupExperimental Treatment1 Intervention
Determination of human dosimetry of the investigation drug [68Ga]P15-041
Group II: Dynamic imaging groupExperimental Treatment1 Intervention
Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[68Ga]P15-041
2016
Completed Early Phase 1
~20
Find a Location
Who is running the clinical trial?
Five Eleven Pharma, Inc.Lead Sponsor
5 Previous Clinical Trials
396 Total Patients Enrolled
3 Trials studying Prostate Cancer
378 Patients Enrolled for Prostate Cancer
Share this study with friends
Copy Link
Messenger